Evaluation of the Relationship between Prostate Cancer and Serum Inflammation Markers

Background and Aims: In this study, we aimed to examine possible relationship between the serum inflammation markers such as C-reactive protein (CRP), lactate dehydrogenase (LDH), erythrocyte sedimantation rate (ESR), ceruloplasmin; and the stage of prostate cancer (Pca), serum prostate specific antigen (PSA) level and the Gleason score in patients with Pca. Methods: Fourtyone patients diagnosed with prostate cancer, and 46 patients forming the control group, and diagnosed as having benign prostatic hyperplasia (BPH) were included in this study. The prostate cancer group was divided into subgroups according to the following parameters; PSA ≤20 ng/ ml and >20 ng/ ml, Gleason scores of ≤6 and >6, and further the cases with and without bone metastasis. Results: It was detected that serum levels of CRP, ceruloplasmin and ESR were significantly higher in prostate cancer group, compared with the control group (p<0,05). Serum levels of CRP, ceruloplasmin, LDH and ESR were significantly higher in the Pca group with Gleason score of >6 compared with the Pca patients Gleason score ≤6 (p<0.05). Also, CRP, ceruloplasmin, alkaline phosphatase (ALP), LDH and ESR were significantly higher in the patients with PSA>20 ng/ ml, compared with the ones with serum PSA levels≤20 ng/ ml in the Pca group, as well (p<0.05). Conclusions: We conclude that the serum inflammation markers are elevated significantly higher in patients with prostate cancer, especially for the ones with higher PSA and Gleason score.